Global variations in lung cancer incidence by histological subtype in 2020: a population-based study

Yanting Zhang 1, Salvatore Vaccarella 2, Eileen Morgan 2, Mengmeng Li 3, Jaione Etxeberria 4, Eric Chokunonga 5, Shyam Shunker Manraj 6, Bakarou Kamate 7, Abidemi Omonisi 8, Freddie Bray 9
Affiliations Expand
PMID: 37837979 DOI: 10.1016/S1470-2045(23)00444-8

Abstract

Background: Lung cancer is the second most common cancer worldwide, yet the distribution by histological subtype remains unknown. We aimed to quantify the global, regional, and national burden of lung cancer incidence for the four main subtypes in 185 countries and territories.

Methods: In this population-based study, we used data from Cancer Incidence in Five Continents Volume XI and the African Cancer Registry Network to assess the proportions of adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma among all lung cancers by country, sex, and age group and subsequently applied these data to corresponding national (GLOBOCAN) estimates of lung cancer incidence in 2020. Unspecified morphologies were reallocated to specified subtypes. Age-standardised incidence rates were calculated using the world standard population to compare subtype risks worldwide, adjusted for differences in age composition between populations by country.

Findings: In 2020, there were an estimated 2 206 771 new cases of lung cancer, with 1 435 943 in males and 770 828 in females worldwide. In males, 560 108 (39%) of all lung cancer cases were adenocarcinoma, 351 807 (25%) were squamous cell carcinoma, 163 862 (11%) were small-cell carcinoma, and 115 322 (8%) were large-cell carcinoma cases. In females, 440 510 (57%) of all lung cancer cases were adenocarcinoma, 91 070 (12%) were squamous cell carcinoma, 68 224 (9%) were small-cell carcinoma, and 49 246 (6%) were large-cell carcinoma cases. Age-standardised incidence rates for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, were estimated to be 12·4, 7·7, 3·6, and 2·6 per 100 000 person-years in males and 8·3, 1·6, 1·3, and 0·9 per 100 000 person-years in females worldwide. The incidence rates of adenocarcinoma exceeded those of squamous cell carcinoma in 150 of 185 countries in males and in all 185 countries in females. The highest age-standardised incidence rates per 100 000 person-years for adenocarcinoma, squamous cell carcinoma, small-cell carcinoma, and large-cell carcinoma, respectively, for males occurred in eastern Asia (23·5), central and eastern Europe (17·5), western Asia (7·2), and south-eastern Asia (11·0); and for females occurred in eastern Asia (16·0), northern America (5·4), northern America (4·7), and south-eastern Asia (3·4). The incidence of each subtype showed a clear gradient according to the Human Development Index for male and female individuals, with increased rates in high and very high Human Development Index countries.

Interpretation: Adenocarcinoma has become the most common subtype of lung cancer globally in 2020, with incidence rates in males exceeding those of squamous cell carcinoma in most countries, and in females in all countries. Our findings provide new insights into the nature of the global lung cancer burden and facilitates tailored national preventive actions within each world region.

Funding: None.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests We declare no competing interests.

Comment in

  • Lessons and opportunities from improved understanding of global lung cancer histological subtypes.

    Cooper WA.Lancet Oncol. 2023 Nov;24(11):1159-1161. doi: 10.1016/S1470-2045(23)00475-8. Epub 2023 Oct 11.PMID: 37837980 No abstract available.

Similar articles

  • The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

    GBD 2017 Oesophageal Cancer Collaborators.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597. doi: 10.1016/S2468-1253(20)30007-8. Epub 2020 Apr 1.PMID: 32246941 Free PMC article.
  • Global incidence of oesophageal cancer by histological subtype in 2012.

    Arnold M, Soerjomataram I, Ferlay J, Forman D.Gut. 2015 Mar;64(3):381-7. doi: 10.1136/gutjnl-2014-308124. Epub 2014 Oct 15.PMID: 25320104
  • The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.

    Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M.Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4.PMID: 35671803 Review.
  • Histological subtype of lung cancer in relation to socio-economic deprivation in South East England.

    Bennett VA, Davies EA, Jack RH, Mak V, Møller H.BMC Cancer. 2008 May 19;8:139. doi: 10.1186/1471-2407-8-139.PMID: 18489782 Free PMC article.
  • Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review.

    Lee PN, Forey BA.BMC Cancer. 2013 Apr 9;13:189. doi: 10.1186/1471-2407-13-189.PMID: 23570286 Free PMC article. Review.
See all similar articles

Cited by

  • Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules.

    Tu M, Wang X, Liu H, Jia H, Wang Y, Li J, Zhang G.Sci Rep. 2024 Sep 28;14(1):22532. doi: 10.1038/s41598-024-73542-1.PMID: 39341939 Free PMC article.
  • Enhancing Immunotherapy Response Prediction in Metastatic Lung Adenocarcinoma: Leveraging Shallow and Deep Learning with CT-Based Radiomics across Single and Multiple Tumor Sites.

    Masson-Grehaigne C, Lafon M, Palussière J, Leroy L, Bonhomme B, Jambon E, Italiano A, Cousin S, Crombé A.Cancers (Basel). 2024 Jul 8;16(13):2491. doi: 10.3390/cancers16132491.PMID: 39001553 Free PMC article.
  • Dual Oncological Challenges: Management of Simultaneous Lung Adenocarcinoma and Primary Cardiac Lymphoma.

    Strike A, Vidal M, Khan P, Barker SB, Bongu N.Cureus. 2024 Jun 28;16(6):e63396. doi: 10.7759/cureus.63396. eCollection 2024 Jun.PMID: 39070460 Free PMC article.
  • Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age.

    Dmukauskas M, Cioffi G, Waite KA, Mammoser AG, Sloan AE, Ma PC, Barnholtz-Sloan JS.Cancers (Basel). 2024 Aug 28;16(17):2986. doi: 10.3390/cancers16172986.PMID: 39272844 Free PMC article.
  • PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.

    Ge Y, Zhan Y, He J, Li J, Wang J, Wei X, Wang C, Gao A, Sun Y.J Cancer Res Clin Oncol. 2024 Mar 18;150(3):135. doi: 10.1007/s00432-024-05637-1.PMID: 38499838 Free PMC article.

Leave a Reply

Your email address will not be published. Required fields are marked *